Background Screening for breast cancer and cervical cancer in the newly independent states of the former Soviet Union is largely opportunistic, and countries in the region have among the highest cervical cancer incidence in the WHO European Region. We aimed to compare the stage-specific distributions and changes over time in breast cancer and cervical cancer incidence in the newly independent states of the former Soviet Union.Methods We collected breast cancer and cervical cancer incidence data from official statistics from Armenia,

No abstract

Relevance: Globocan reports 19.3 million new cases of malignant neoplasms in 2020 globally. Mammary gland cancer has become the most commonly diagnosed oncological pathology, followed by lung, colon and rectum, prostate, and stomach cancers. In Uzbekistan, malignant neoplasms of the breast, stomach, cervix, lungs, and brain dominate the structure of cancer incidence. The study aimed to analyze the cancer incidence trends and structure in the Republic of Uzbekistan in 2020. Results: In 2020, 21976 new cancer cases were registered in Uzbekistan. The ratio of men and women newly diagnosed with cancer was 0.7:1.4. Cancers of the breast, cervix, and ovary were the most common in women; cancers of the stomach, lung, and prostate — in men. Hemoblastoses were more common at a young age, breast cancer – at working age, and stomach cancer – at old age. Conclusions: The statistical information analysis showed that in 2020 the cancers of the mammary gland, stomach, and cervix were leading in the overall cancer structure, with significant differences in different age categories. This determines the need for further improvement of cancer care in Uzbekistan.

No abstract

INNO-LiPA Extra-II kit (Fujirebio), based on PCR-reverse hybridization. Results Among 110 women with CIN2/3 (n=19) and invasive cancer (n=91), early antibodies to any HPV early antigen were detected in 58(53%). The difference between CIN2/3 (47.4%) and cancer (53.8%) was not significant (p=0.62). All 58 were positive for antibodies to HPV16 CE2/NE6/E7. HPV18/31/45 E7 antibodies were detected additionally in 1,1 and 2 cases, respectively. Among 40 controls (normal cytology and negative HPV DNA on Hybrid Capture), any early HPV antibodies were detected in 8(20.0%) cases with HPV16 CE2/ NE6/E7 in 3(7.5%), HPV18 E7 in 2(5%), HPV31 E7 in 5 (12.5%), and HPV45 E7 in 3(7.5%). On HPV genotyping, 88 (80.0%) cases had any high-risk (hr)HPV type, commonest being HPV16(69%), HPV18(5%), HPV31/33(3% each), HPV35/45/59(2% each). Single hrHPV infections were detected in 77 patients, 7 had single hrHPV infections other than HPV16. Multiple hrHPV infections were detected in 11 (10%) patients. Conclusions The serological test detects a high proportion of cases detected by INNO-LiPA. Further development of this simple, affordable technology holds promise to facilitate cervical screening and triage in community settings.